DOTS: Dalbavancin for S. aureus Bacteremia

Whitney and panel review DOTS trial showing dalbavancin noninferior clinically but not superior; discusses real‑world use and patient preferences.

Play episode from 01:03:46

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!